As of the last check today, BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares were trading 23.20% up at $4.62 on the stock charts. The surge followed the company’s positive clinical trial results.
Excellent Results for HR+ Metastatic Breast Cancer
Following the publication of revised results from its Phase 2 study assessing the Bria-IMT regimen in conjunction with checkpoint inhibitors (CPI), which demonstrated improved survival outcomes in patients with metastatic breast cancer (MBC), BCTX stock experienced a strong increase.
Patients with late-stage MBC, especially those with hormone receptor-positive (HR+) illness, were the focus of the Phase 2 investigation. Twenty-five of the 37 patients who received treatment with BriaCell’s current pivotal Phase 3 formulation of Bria-IMT were found to be HR+.
The median survival for these patients was 17.3 months, which was higher than the 14.4-month survival with TRODELVY, an antibody-drug conjugate (ADC) that is thought to be the standard of therapy for this population.
Boosting Triple-Negative Breast Cancer Outcomes
In the triple-negative breast cancer (TNBC) group, a particularly difficult subtype devoid of HER2, progesterone, and estrogen receptors, the Bria-IMT + CPI regimen also produced noteworthy outcomes. While survival in this group was comparable to that achieved with TRODELVY, it exceeded traditional chemotherapy outcomes by 70%, underscoring the regimen’s therapeutic potential.
Well-Tolerated Therapy Shows Broad Potential
There have been no documented treatment-related discontinuations as of yet, indicating that the Bria-IMT regimen has shown excellent tolerability. These results support BriaCell’s theory that Bria-IMT and CPI together might provide HR+ and TNBC patients—groups who presently have few therapy options and dismal prognoses—with a useful treatment option.
Of the 54 patients with MBC who were significantly pre-treated in BriaCell’s Phase 2 study, 37 were given the formulation that is currently being employed in its key Phase 3 trial. BCTX will continue evaluating overall survival as the primary endpoint in this ongoing study, aiming to confirm the promising Phase 2 results and address the unmet medical needs in this difficult-to-treat population.
